Aptose Biosciences Enters Acquisition Agreement with Hanmi Pharmaceutical
Aptose Biosciences Inc. (TSX: APS, OTC: APTOF) has announced a significant arrangement agreement with Hanmi Pharmaceutical Co. Ltd. that will see all issued common shares of Aptose, not already held by Hanmi or its affiliates, acquired by them. This move marks a pivotal moment in the operations of Aptose, propelling their oncology endeavors into a new chapter.
Details of the Arrangement Agreement
The agreement involves not only a strategic acquisition but also the financial backing that Hanmi has provided over recent periods. They own approximately 19.93% of Aptose's common shares and have supported the company with over US$30 million in debt facilities for the development of its lead compound, tuspetinib (TUS).
Financial Implications for Shareholders
Upon the completion of the acquisition, shareholders of Aptose, excluding the Hanmi affiliates, will receive a cash amount of C$2.41 per common share. This figure reflects a substantial premium of 28% compared to Aptose's 30-day volume-weighted average price (VWAP) of C$1.88. Therefore, the offer presents a lucrative opportunity for minority shareholders.
Future Developments with Tuspetinib
William G. Rice, the Chairman, President, and CEO of Aptose expressed his enthusiasm about the agreement, stating it provides not only a premium for shareholders but also ensures continuous development of TUS combined with existing treatments for acute myeloid leukemia (AML). Early clinical trials showcased promising results, and this acquisition could enhance further research and patient outcomes significantly.
Hanmi's Strategic Expansion into North America
The acquisition signifies Hanmi’s first substantial entry into the North American biopharmaceutical market. Jae-Hyun Park from Hanmi emphasized the importance of supporting the ongoing development of tuspetinib, aiming to leverage strong data for future clinical expansions.
Transaction Logistics and Requirements
Transitioning Aptose from a corporation established under the Canada Business Corporations Act to one governed by the Business Corporations Act (Alberta) will continue under the framework of this agreement. Shareholder approval, as well as court sanctions, are crucial components for the finalization of this acquisition.
The shareholders of Aptose are expected to approve the agreement by voting at a special meeting set to occur by January 16, 2026. This approval will include a two-thirds majority requirement, excluding votes from Hanmi affiliates.
Evaluating the Fairness of the Transaction
To ensure that the arrangement is in the best interests of Aptose shareholders, Locust Walk Securities, LLC was appointed to conduct a formal valuation. Their assessment placed the fair market value of Aptose shares within a range of C$1.00 to C$5.23, highlighting the offer as fair from a financial standpoint.
The Role of the Aptose Board
Both the Special Committee and the Board of Directors of Aptose have unanimously approved the proposed arrangement, reflecting their confidence in the benefits this acquisition will bring to the company and its shareholders.
About Tuspetinib and its Impact on AML Treatment
The ongoing TUSCANY Phase 1/2 study is a crucial component of Aptose's research into its lead compound, tuspetinib. This therapy focuses on providing effective treatment options for newly diagnosed AML patients who are ineligible for induction chemotherapy. The outcomes to date indicate a high response rate, offering hope for patients facing difficult diagnoses.
Background on Hanmi Pharmaceutical
Hanmi Pharmaceutical, founded in 1973 in South Korea, has established itself as a key player in biopharmaceuticals, focusing on innovative cancer therapies and other diseases. With geographic expansion into North America, the company aims to enhance its collaborative partnerships and increase its global footprint.
Contact Information for Aptose Biosciences Inc.
For more information regarding this acquisition and future developments, you can reach Aptose as follows:
Aptose Biosciences Inc.
Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com
Frequently Asked Questions
What is the acquisition deal between Aptose and Hanmi?
Aptose is set to be acquired by Hanmi Pharmaceutical, with shareholders receiving C$2.41 for each share owned, marking a premium over recent trading prices.
When will the shareholder meeting occur?
The special meeting for Aptose's shareholders is scheduled no later than January 16, 2026, to vote on the acquisition agreement.
What is tuspetinib, and why is it significant?
Tuspetinib (TUS) is a key drug in Aptose's pipeline, aimed at treating acute myeloid leukemia. Its clinical trials have shown promising safety and efficacy.
Who conducted the valuation of Aptose's shares?
Locust Walk Securities was retained to provide an independent valuation of Aptose's shares to ensure fairness in the acquisition offer.
What is Hanmi's strategy in North America?
Hanmi aims to establish a strategic presence in North America through the acquisition, enabling future partnerships and clinical development opportunities.
